{"entity":{"id":"nct07087158","kind":"trial","name":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of Pazopanib in renal cell carcinoma, run by Imbioray (Hangzhou) Biomedicine Co., Ltd., now recruiting.","summary":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma is a phase 2 interventional study registered as NCT07087158 by Imbioray (Hangzhou) Biomedicine Co., Ltd., with 30 participants planned, started 2025-09-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: IBR854, Pazopanib. Conditions listed: Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07087158","url":"https://clinicaltrials.gov/study/NCT07087158"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["pazopanib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07087158","phase":"2","setting":"A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","sponsor":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","participation":[{"nct":"NCT07087158","source":"https://clinicaltrials.gov/study/NCT07087158","fetchedAt":"2026-10-07T16:55:25.997Z","studySha256":"b1583b99c75908d408a58837f11da1328e4b674c567e8c7fbc2d5921975b0d5c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-02","leadSponsor":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":30,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-09-08","startedType":"actual","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07087158/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/"}]}}